What is it about?
A Trial in 12 208 people randomised to standard NHS care or a seven autoantibody panel test followed by Low dose CT for those who tested positive. At two years, 127 lung cancers were detected in the study population (1.0%). In the intervention arm, 33/56 (58.9%) lung cancers were diagnosed at stage III/IV compared to 52/71 (73.2%) in the control arm. The hazard ratio for stage III/IV presentation was 0.64 (95% confidence interval 0.41, 0.99). There were non-significant differences in lung cancer and all-cause mortality after two years.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
ECLS compared EarlyCDT-Lung plus CT screening to standard clinical care (symptomatic presentation), and was not designed to assess the incremental contribution of the EarlyCDT-Lung test. The observation of a stage-shift towards earlier-stage lung cancer diagnosis merits further investigations to evaluate whether the EarlyCDT-Lung test adds value to the emerging standard of LDCT in lung cancer screening.
Perspectives
Although Lung Cancer is a major cause of death and traetments are improving all the time, early diagnosis will be key to making advances in reducing morbidity and mortality.
Frank Sullivan
University of Saint Andrews
Read the Original
This page is a summary of: Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging, European Respiratory Journal, July 2020, European Respiratory Society (ERS),
DOI: 10.1183/13993003.00670-2020.
You can read the full text:
Resources
Contributors
The following have contributed to this page
